Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
756 stopped studies mapped to Acute Leukemia and descendants · 89% state a reason
Over the 756 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00579111 | Reduced Intensity Preparative Regimen Followed by Stem Cell Transplant (FAB) | Phase 1 / Phase 2 | terminated | Dec 21, 2007 | Baylor College of Medicine | slow accrual | Enrollment / accrual |
| NCT02221505 | Phase 1 Study of LOP628 in Adult Patients With cKit-positive Solid Tumors and Acute… | Phase 1 | terminated | Aug 20, 2014 | Novartis Pharmaceuticals | not stated | Not stated |
| NCT01573247 | Safety Study of AKN-028 in Patients With Acute Myelogenous Leukemia | Phase 1 / Phase 2 | terminated | Apr 9, 2012 | Akinion Pharmaceuticals AB | During the study two patients have experienced serious liver events related to AKN-028. The… | Other (stated, no rule matched) |
| NCT01455025 | Study in Plerixafor and Granulocyte-colony Stimulating Factor Patients With Relapse Acute…(PRIMAL) | Phase 1 | terminated | Oct 19, 2011 | French Innovative Leukemia Organisation | no recruitment on time | Enrollment / accrual |
| NCT00664677 | Phase 1 Study of Terameprocol (EM-1421) in Patients With Leukemia | Phase 1 | terminated | Apr 23, 2008 | Erimos Pharmaceuticals | Funding constraints | Funding |
| NCT00349518 | Study of Dasatinib in Imatinib Resistant or Intolerant Subjects With Chronic or Advanced… | Phase 2 / Phase 3 | withdrawn | Jul 7, 2006 | Bristol-Myers Squibb | not stated | Not stated |
| NCT00660036 | Phase I/II Study of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin for Acute Myeloid… | Phase 1 | terminated | Apr 17, 2008 | University of Pittsburgh | due to new safety information | Safety / toxicity |
| NCT01067274 | ALFA-0703 Study in Older Patients With Acute Myeloblastic Leukemia (AML)(ALFA-0703) | Phase 3 | withdrawn | Feb 11, 2010 | Acute Leukemia French Association | Study abandoned | Other (stated, no rule matched) |
| NCT00866281 | A Study of the Safety and Preliminary Efficacy of Oral Midostaurin (PKC412) in Relapsed… | Phase 1 / Phase 2 | terminated | Mar 20, 2009 | Novartis Pharmaceuticals | Despite considerable efforts to boost recruitment during the final year of the study, no new… | Enrollment / accrual |
| NCT01049113 | Safety Study of ON 013105 in Lymphoma and Acute Lymphoid Leukemia | Phase 1 | terminated | Jan 14, 2010 | Traws Pharma, Inc. | Lack of available clinical drug supply | Drug supply |
| NCT01624701 | Clinical Ex Vivo Expansion of Human Umbilical Cord Blood Stem and Progenitor Cells | Phase 1 / Phase 2 | terminated | Jun 21, 2012 | Singapore General Hospital | Funding expired | Funding |
| NCT02034227 | Safety, Tolerability Study of SG2000 in the Treatment of Advanced Chronic Lymphocytic… | Phase 1 / Phase 2 | terminated | Jan 13, 2014 | Spirogen | not stated | Not stated |
| NCT01670084 | Nilotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed… | Phase 2 | withdrawn | Aug 21, 2012 | Mayo Clinic | No Accrual | Enrollment / accrual |
| NCT00670150 | New Retinoid Agent Combined With Arsenic Trioxide for Untreated Acute Promyelocytic… | Phase 2 | withdrawn | May 1, 2008 | University of Southern California | sponsor withdrew support | Other (stated, no rule matched) |
| NCT00860535 | Growth Factor Signature (GFS) Pilot Study (MK0000-098)(COMPLETED) | Phase 1 | terminated | Mar 12, 2009 | Merck Sharp & Dohme LLC | not stated | Not stated |
| NCT01794169 | Azacitidine Compared to Conventional Chemotherapy as Consolidation of Elderly Patients… | Phase 2 | terminated | Feb 18, 2013 | Karolinska University Hospital | Poor recruitment | Enrollment / accrual |
| NCT02338050 | Moxetumomab Pasudotox (CAT-8015, HA22) in Children With B-lineage Acute Lymphoblastic… | Phase 2 | terminated | Jan 14, 2015 | Center for International Blood and Marrow Transplant Research | not stated | Not stated |
| NCT01260714 | Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With… | Phase 1 | terminated | Dec 15, 2010 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT02109224 | Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With… | Phase 1 | terminated | Apr 9, 2014 | National Cancer Institute (NCI) | Inadequate accrual rate | Enrollment / accrual |
| NCT01489722 | Safety, Tolerability, Pharmacokinetics and Efficacy of AZD1208 in Acute Myelogenous… | Phase 1 | terminated | Dec 12, 2011 | AstraZeneca | not stated | Not stated |
| NCT01908387 | Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms | Phase 1 | terminated | Jul 25, 2013 | Celgene Corporation | Due to Slow Accrual study was terminated. | Enrollment / accrual |
| NCT00905398 | Nilotinib With Chemotherapy for the Treatment of Philadelphia Chromosome Positive Acute…(ALLPhi) | Phase 1 / Phase 2 | terminated | May 20, 2009 | Rony Schaffel | The study was terminated due to excessive toxicity and low compliance to the protocol scheme. | Safety / toxicity |
| NCT00374296 | MGCD0103 in Elderly Patients With Previously Untreated AML/High Risk MDS or Adults With… | Phase 2 | terminated | Sep 11, 2006 | Mirati Therapeutics Inc. | The Clinical Development Program for MGCD0103 is being re-evaluated | Other (stated, no rule matched) |
| NCT00963495 | Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients… | Phase 1 | terminated | Aug 21, 2009 | University Health Network, Toronto | not stated | Not stated |
| NCT01222143 | Safety and Efficacy Study of Nilotinib Combined With Mitoxantrone, Etoposide, and… | Phase 1 / Phase 2 | terminated | Oct 18, 2010 | University Health Network, Toronto | not stated | Not stated |
| NCT01521936 | Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive… | Phase 2 | terminated | Jan 31, 2012 | Roswell Park Cancer Institute | Lack of funding | Funding |
| NCT00666497 | Phase 2 Study of Azacitidine (Vidaza) vs MGCD0103 vs Combination in Elderly Subjects With… | Phase 2 | terminated | Apr 25, 2008 | Mirati Therapeutics Inc. | Celgene terminated its collaboration agreement with MethylGene for the development of MGCD0103. All… | Other (stated, no rule matched) |
| NCT00944008 | PROCEDYTE: Depocyte® Administration (Liposomal Cytarabine) as Prophylaxis of…(2009-009422-92) | Phase 3 | terminated | Jul 22, 2009 | PETHEMA Foundation | not stated | Not stated |
| NCT00262925 | Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory… | Phase 2 | terminated | Dec 7, 2005 | National Cancer Institute (NCI) | slow accrual | Enrollment / accrual |
| NCT00669890 | Allogenic Stem Cell Transplantation in Patients With High Risk CD33+ AML/MDS/JMML(High Risk) | Phase 1 | terminated | May 1, 2008 | New York Medical College | PI left institution | Investigator |
| NCT00943553 | A Randomized Study of Epigenetic Priming Using Decitabine With Front Line Induction… | Phase 2 | withdrawn | Jul 22, 2009 | Eisai Inc. | Terminated by Sponsor | Other (stated, no rule matched) |
| NCT01065545 | The Role of Maintenance Oral Clofarabine in Older Adults With Acute Myeloid Leukemia | Phase 1 | withdrawn | Feb 9, 2010 | Northwestern University | Due to funding issues. | Funding |
| NCT01203228 | Dose-reduced Versus Standard Conditioning in MDS/sAML(RICMAC) | Phase 3 | terminated | Sep 16, 2010 | European Society for Blood and Marrow Transplantation | not stated | Not stated |
| NCT01488253 | Sirolimus/Tacrolimus Combination After HLA Matched Related Peripheral Blood Stem Cell… | Phase 2 | terminated | Dec 8, 2011 | The Korean Society of Blood and Marrow Transplantation | We could not receive the support from the national medical insurance owing to the changed policy of… | Other (stated, no rule matched) |
| NCT01100658 | Effects of Methylphenidate on Attention Deficits in Childhood Cancer Survivors | N/A | terminated | Apr 9, 2010 | University of Minnesota | Due to slow accrual | Enrollment / accrual |
| NCT01010373 | Safety and Efficacy Study of AS101 to Treat Elderly Acute Myeloid Leukemia (AML) and… | Phase 2 | suspended | Nov 10, 2009 | BioMAS Ltd | The sponsor is currently focusing on different indications | Other (stated, no rule matched) |
| NCT00798213 | SCH 727965 in Patients With Acute Myelogenous Leukemia and Acute Lymphoblastic Leukemia… | Phase 2 | terminated | Nov 26, 2008 | Merck Sharp & Dohme LLC | not stated | Not stated |
| NCT01486043 | Metformin and Transient Hyperglycemia | N/A | terminated | Dec 6, 2011 | Children's Hospital Los Angeles | The research project was terminated due to lower than projected patient recruitment within the… | Enrollment / accrual |
| NCT00907582 | ASCT for Relapsed APL After Molecular Remission | Phase 2 | terminated | May 22, 2009 | Shanghai Jiao Tong University School of Medicine | slow recruitment | Enrollment / accrual |
| NCT01230788 | Rituximab for Patients With Relapsed Acute Lymphoblastic Leukemia(Rituximab) | N/A | terminated | Oct 29, 2010 | Emory University | Lack of enrollment | Enrollment / accrual |
| NCT02238522 | Phase 1 Study Evaluating ZEN003365 in Relapsed/Refractory Lymphoproliferative… | Phase 1 | withdrawn | Sep 12, 2014 | Zenith Epigenetics | not stated | Not stated |
| NCT01088763 | Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or… | Phase 1 | terminated | Mar 17, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00594308 | In-Vivo Activated T-Cell Depletion to Prevent GVHD | N/A | terminated | Jan 15, 2008 | Indiana University | Treatment ineffective | Other (stated, no rule matched) |
| NCT00967512 | Aezea® (Cenersen) and Chemotherapy for AML Subjects ≥ 55 Years of Age With No Response to… | Phase 2 | withdrawn | Aug 28, 2009 | Eleos, Inc. | Study Was Terminated due to lack of Funding. | Funding |
| NCT00593645 | Clofarabine, Cytarabine, and Thymoglobulin for Allogeneic Transplantation | Phase 2 | terminated | Jan 15, 2008 | Washington University School of Medicine | toxicities were worse than expected | Safety / toxicity |
| NCT01688752 | Cardiometabolic Status in Childhood Acute Lymphoblastic Leukemia | — | withdrawn | Sep 20, 2012 | University of Minnesota | Funding unavailable | Funding |
| NCT00184054 | Trial of Arsenic Trioxide With Ascorbic Acid in the Treatment of Adult Non-Acute… | Phase 2 | terminated | Sep 16, 2005 | University of Southern California | Competing studies | Other (stated, no rule matched) |
| NCT00387426 | Sunitinib in Treating Patients With Idiopathic Myelofibrosis | Phase 2 | terminated | Oct 13, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00933985 | Obatoclax Mesylate, Vincristine Sulfate, Doxorubicin Hydrochloride, and Dexrazoxane… | Phase 1 | terminated | Jul 8, 2009 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01193400 | Clofarabine and Low-dose Cytarabine Followed by Consolidation Therapy in AML Patients Age… | Phase 2 | terminated | Sep 1, 2010 | PETHEMA Foundation | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated May 4, 2016source: clinicaltrials